- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
This report provides in-depth technical discussions in areas that have direct implications to the containment of AMR as a development agenda. The report is organized in five chapters which served as the technical background documents for the Biregional Technical Consultation on AMR in Asia, 14-15 April 2016. More information from the meeting is available in the WHO Meeting Report: Biregional Technical Consultation on Antimicrobial Resistance in Asia. The meeting was the first time senior officials from the Ministry of Health and Ministry of Agriculture across Asia came together to tackle AMR.
Keywords: drug resistance, microbial, infection control
This report highlights the key results achieved over Phase II of the MHTF, from 2014 to 2016, structured around the three cross-cutting principles of accountability, equality of access and quality of care, as outlined in the MHTF Business Plan Phase II (2014-2017). The report foregrounds the MHTF’s role in supporting health systems strengthening, and addresses its catalytic nature, its promotion of sustainability and its strong emphasis on advancing innovation.
Saving lives, preventing new HIV infections, preventing mother-to-child transmission of HIV, post-exposure prophylaxis for averting HIV infection, restoring respect and dignity to people living with HIV, pre-exposure prophylaxis for people at higher risk, preventing TB, TB-related deaths and TB transmission, restoring employment, reducing the number of children becoming orphans, and reducing maternal mortality.
The present guidance was developed with the support of the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) to assist countries and other stakeholders in the establishment and development of programmes of integrated surveillance of antimicrobial resistance in the foodborne bacteria (i.e., bacteria commonly transmitted by food) by taking a One Health approach. This guidance document replaces the previous version published in 2013.
Keywords: antimicrobial use, analysis, reporting, data
This book represents the consolidated knowledge and experience related to the policies and management of universal access to ART in Thailand. It aims to serve as an important tool to share knowledge with and advocate the policy of universal health coverage (UHC) to policymakers in the other developing nations that are working towards achieving UHC inclusive of the continuum of HIV and AIDS care services
Keywords: Thailand, HIV, PLHIV, ART, treatment, health system
This report is an account of the Region’s progress in developing and implementing NAPs. The report provides a platform to track what is going well, and to identify areas where extra efforts are needed. In the report, the regional roadmap for strengthening national AMR prevention and containment programmes is analysed with a specific methodology. The results gathered have been compiled to contribute to country profiles which make the report more useful.
Keywords: AMR, situation analysis, surveillance, prevention
Drug use and supply have been a sensitive and high-priority issue for successive governments in China since at least the Opium Wars in the mid-19th century. China’s policy response to drug use relies on punishment and coercion as central components, including compulsory detoxification, detention in labour camps or so-called ‘rehabilitation’ facilities, and compulsory registration with law enforcement authorities resulting in surveillance and random interrogations.
Yet, in the late-1990s, in a policy move that appeared to emphasize healthcare instead of punishment for people who inject drugs, China began implementing the world’s largest scale-up provision of opioid substitution therapy (OST) and needle and syringe programmes (NSP) – two critical harm reduction measures for preventing HIV transmission. However, the overall approach towards people who use drugs remains punitive and stigmatising in China. As drug use continues to rise and expand across a greater range of drugs (especially synthetic drugs such as methamphetamine), as well as amongst younger age groups, China requires a comprehensive system of evidence-based and humane drug treatment and harm reduction services capable of advancing the health and quality of life of individuals and communities.
Keywords: China, HIV, PWID, NSPs and OST, drugs, health, law
WHO has recommended adopting drug regimens with high potency, lower toxicity, high genetic barriers to resistance, usefulness across different populations and lower cost. The use of optimized drug regimens can improve the durability of the treatment and quality of care of people living with HIV.
Adopting optimized antiretroviral (ARV) drug regimens can significantly affect the speed at which the 90 –90 –90 targets are achieved, enhancing access to treatment and improving treatment outcomes with impact on treatment adherence, viral suppression and the quality of life of people living with HIV, reducing pressures on health systems and the risk of HIV transmission.
This WHO Global hepatitis report describes, for the first time, the global and regional estimates on viral hepatitis in 2015, setting the baseline for tracking progress in implementing the new global strategy.
The report focuses on hepatitis B and C, which are responsible for 96% of all hepatitis mortality. It presents data along the five strategic directions (strategic information, interventions, equity, financing and innovation) – key pillars of the GHSS to facilitate monitoring of progress in countries, regions and globally, and to measure the impact of interventions on reducing new infections and saving lives between 2015 and 2030.
Download Executive Summary
The world has embraced the UNAIDS 90–90–90 treatment target, whereby 90% of people living with HIV know their HIV status, 90% of people who know their HIV-positive status are accessing antiretroviral treatment, and 90% of people on treatment have suppressed viral loads. By reaching the 90–90–90 treatment target by 2020, the world will be firmly on track towards ending the AIDS epidemic by 2030.
Keywords: HIV, treatment, HLM2016AIDS, ART, Fast-Track